

UNITED STATES DISTRICT COURT
FOR THE WESTERN DISTRICT OF TEXAS
AUSTIN DIVISION

INFORMED CONSENT ACTION NETWORK,

Plaintiff,

-against-

CENTERS FOR DISEASE CONTROL AND
PREVENTION AND HEALTH AND HUMAN
SERVICES,

Defendant.

Civil Action No. 1:22-cv-481

COMPLAINT FOR DECLARATORY AND INJUNCTIVE RELIEF

Plaintiff, as for its Complaint regarding a Freedom of Information Act request against the above-captioned Defendant, alleges as follows:

INTRODUCTION

1. Between December 2020 and February 2021, the Food and Drug Administration (“FDA”) issued Emergency Use Authorizations for three COVID-19 vaccines,¹ one of which subsequently received FDA approval in August 2021 and another on January 31, 2022.² While the FDA approved these vaccines, the Centers for Disease Control and Prevention (“CDC”), an agency within the Department of Health and Human Services (“HHS”), is charged with

¹ <https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19> (last visited May 11, 2022); <https://http://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid> (last visited May 11, 2022); <https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine> (last visited May 11, 2022).

² <https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine> (last visited May 11, 2022); <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine> (last visited May 11, 2022).

monitoring the safety of all vaccines, including the COVID-19 vaccines approved by the FDA. The CDC claims that these “COVID-19 vaccines are being administered under the **most intensive vaccine safety monitoring effort in U.S. history[.]**”³

2. The federal government has mandated that millions of Americans receive these vaccine products. HHS has also given pharmaceutical companies complete immunity for injuries caused by those products. Mandating that millions of Americans inject a product for which they cannot hold the manufacturer liable if the product injures them demands complete **transparency**, especially when it comes to releasing the data underlying the product’s safety. FOIA exists precisely so that the American people can obtain transparency and, in this case, obtain the data which supports the CDC’s claims to intensive safety monitoring.

3. The FDA and CDC have said that their prior primary existing vaccine safety monitoring program was incapable of determining causation and was otherwise unreliable to assess the safety of COVID-19 vaccines, and hence deployed a new safety monitoring system for the COVID-19 vaccines, v-safe.

4. V-safe is a smartphone app that allows vaccine recipients to “tell CDC about any side effects after getting the COVID-19 vaccine.”⁴ The purpose of the app “is to rapidly characterize the safety profile of COVID-19 vaccines when given outside a clinical trial setting and to detect and evaluate clinically important adverse events and safety issues that might impact policy or regulatory decisions.”⁵

5. The CDC has explained that the data submitted to v-safe is “collected, managed,

³ <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/05-COVID-Hause-508.pdf> (last visited May 11, 2022).

⁴ <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html> (last visited May 11, 2022).

⁵ <https://www.cdc.gov/vaccinesafety/pdf/V-safe-Protocol-508.pdf> (last visited May 11, 2022).

and housed on a secure server by Oracle,”⁶ a private computer technology company. Although the CDC has “access to the individualized survey data,” Oracle has access to “aggregate deidentified data for reporting.”⁷

6. Plaintiff asked, through its instant FOIA request, that the CDC produce all data submitted to the v-safe program. To provide transparency regarding the government’s claim that COVID-19 vaccines are “safe and effective,”⁸ the public should have immediate access to all disclosable v-safe data. Hence, once the CDC produces that data, Plaintiff intends to make it publicly available. Even though disclosable data already exists, and even though the CDC has never objected to its production, the CDC has failed to produce it to Plaintiff and the American public. The federal government is thereby not only failing to live up to its promise of transparency but is also failing to comply with FOIA.

7. Plaintiff Informed Consent Action Network (“**Plaintiff**”) is a non-profit organization that advocates for informed consent and transparency, and disseminates information necessary for same with regard to all medical interventions. *See* ICAN’s Declaration (“**Exhibit 1.**”) It intends to make all v-safe data immediately available to the public so that independent scientists can immediately analyze that data. It believes that we need all hands-on deck, both inside and outside the government, to address serious and ongoing issues with the vaccine program,

⁶ <https://www.cdc.gov/vaccinesafety/pdf/V-safe-Protocol-508.pdf> p. 8 (last visited May 11, 2022).

⁷ <https://www.cdc.gov/vaccinesafety/pdf/V-safe-Protocol-508.pdf> p. 9 (last visited May 11, 2022) (emphasis added).

⁸ *See, e.g.*, <https://www.fda.gov/media/146269/download> (materials for February 26, 2021 meeting of the Vaccines and Related Biological Products Advisory Committee (“VRBPAC”) stating “[r]eactogenicity profiles of mRNA vaccines in v-safe monitoring are consistent with what was observed in clinical trials”) (last visited May 11, 2022); <https://www.fda.gov/media/150054/download> (materials from June 10, 2021 meeting of VRBPAC stating “[i]nitial safety findings from Pfizer-BioNTech COVID-19 vaccination of 12-15-year-olds from v-safe and VAERS surveillance are consistent with results from pre-authorization clinical trials”); <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/05-COVID-Hause-508.pdf> (materials from October 21, 2021 meeting of Advisory Committee on Immunization Practices stating “[n]o unexpected patterns of adverse events were identified”) (last visited May 11, 2022).

including waning immunity, adverse reactions, etc. Locking out independent scientists from addressing these issues is, at best, irresponsible and unethical.

8. To make public the v-safe data, Plaintiff made a request to the CDC pursuant to the Freedom of Information Act (5 U.S.C. § 552, as amended) (“**FOIA**”). Plaintiff’s FOIA request was for “[a]ll data submitted to v-safe since January 1, 2020.” The CDC issued an acknowledgment letter regarding ICAN’s request but failed to make a final determination regarding the request within FOIA’s thirty-day time requirement. Plaintiff brings this action to challenge the CDC and HHS’ failure to timely respond to ICAN’s FOIA request.

PARTIES

9. Plaintiff is a not-for-profit organization with an office located at 2025 Guadalupe Street, Suite 260, Austin, Texas 78705. (**Exhibit 1.**)

10. The CDC is an agency within the Executive Branch of the United States Government, organized within HHS. The CDC is an agency within the meaning of 5 U.S.C. § 552(f).

11. HHS is an agency within the Executive Branch of the United States Government. HHS is an agency within the meaning of 5 U.S.C. § 552(f).

JURISDICTION AND VENUE

12. This Court has jurisdiction over this action pursuant to 5 U.S.C. § 552(a)(4)(B) and 28 U.S.C. § 1331. Venue is proper within this District pursuant to 5 U.S.C. § 552(a)(4)(B) and 28 U.S.C. § 1391.

FACTS

A. COVID-19 Vaccines

13. In December 2020, the FDA issued emergency use authorizations for the Pfizer-

BioNTech⁹ and Moderna¹⁰ COVID-19 vaccines. In February 2021, the FDA issued an emergency use authorization for the Janssen COVID-19 vaccine.¹¹ There have been subsequent emergency use authorizations issued for these three vaccines for younger age groups, for boosters, and for “mix and match” administration of the three vaccines. In August 2021, the FDA licensed the Pfizer-BioNTech COVID-19 vaccine for individuals 16 years of age and older.¹²

14. Although all three novel COVID-19 vaccines available in the United States were developed at record pace, these products have been mandated for a majority of Americans under the threat of losing their jobs, being separated from the military, being excluded from university, and from participating in civil society.¹³ The federal government has, for example, issued mandates for private employees, public employees, and the military.¹⁴ Some cities have gone as far as to require COVID-19 vaccines for entry into restaurants, clubs, gyms, entertainment venues, and indoor events.¹⁵

15. While mandating this product, the federal government has also given the

⁹ <https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19> (last visited May 11, 2022).

¹⁰ <https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid> (last visited May 11, 2022).

¹¹ <https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine> (last visited May 11, 2022).

¹² <https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine> (last visited May 11, 2022).

¹³ <https://www.whitehouse.gov/covidplan/> (last visited May 11, 2022).

¹⁴ <https://www.whitehouse.gov/covidplan/> (last visited May 11, 2022); <https://www.federalregister.gov/documents/2021/11/05/2021-23643/covid-19-vaccination-and-testing-emergency-temporary-standard> (last visited May 11, 2022); <https://www.federalregister.gov/documents/2021/11/05/2021-23831/medicare-and-medicaid-programs-omnibus-covid-19-health-care-staff-vaccination> (last visited May 11, 2022); <https://media.defense.gov/2021/Aug/25/2002838826/-1/-1/0/MEMORANDUM-FOR-MANDATORY-CORONA-VIRUS-DISEASE-2019-VACCINATION-OF-DEPARTMENT-OF-DEFENSE-SERVICE-MEMBERS.PDF> (last visited May 11, 2022).

¹⁵ <https://sf.gov/information/vaccine-required> (last visited May 11, 2022); <https://www1.nyc.gov/site/doh/covid/covid-19-vaccines-keytonyc.page> (last visited May 11, 2022).

pharmaceutical companies selling these vaccines, and anyone associated with administering them, complete legal immunity for any injury caused by these vaccines. 42 U.S.C. § 247d-6d (providing that any “manufacturer” of “any vaccine, used to ... prevent or mitigate COVID-19” shall be “immune from suit and liability under Federal and State law with respect to all claims ... resulting from ... [its] use by an individual”). These pharmaceutical companies are even immune from liability for willful misconduct unless the federal government, which promoted and licensed this product, first brings this claim. *Id.*

B. Vaccine Safety Monitoring

16. Because COVID-19 vaccines are being mandated for millions of Americans, it is essential that our federal health agencies ensure that these products are safe and afford the American people transparency regarding the data supporting that claim.

17. The CDC is one of the primary federal agencies responsible for monitoring vaccine safety, including the safety of COVID-19 vaccines. The CDC claims that “COVID-19 vaccines are being administered under **the most intensive vaccine safety monitoring effort in U.S. history[.]**”¹⁶

18. The apparent primary way that the CDC claims to monitor the safety of COVID-19 vaccines is through v-safe app,¹⁷ which “uses text messaging and web surveys to give personalized health check- ins after [one] receives a COVID-19 vaccine.”¹⁸ The app allows users to “quickly tell CDC if [they] have any side effects after getting a COVID-19 vaccine[.]” which “helps CDC monitor the safety of COVID-19 vaccines in near real time.”

¹⁶ <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/05-COVID-Hause-508.pdf> (last visited May 11, 2022).

¹⁷ See <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety.html> (listing v-safe as one of the ways “CDC expanded and strengthened the country’s ability to monitor vaccine safety”) (last visited May 11, 2022).

¹⁸ <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html> (last visited May 11, 2022).

19. On May 20, 2021, the CDC published a document titled “V-safe active surveillance for COVID-19 vaccine safety” (the “**V-Safe Protocol**”).¹⁹ The document explains that “[t]he purpose of v-safe surveillance is to rapidly characterize the safety profile of COVID-19 vaccines when given outside a clinical trial setting and to detect and evaluate clinically important adverse events and safety issues that might impact policy or regulatory decisions.”²⁰

20. The V-Safe Protocol indicates that “V-safe data will be collected, managed, and housed on a secure server by Oracle.”²¹ The V-Safe Protocol further provides:

Oracle staff will not be able to view any individualized survey data (including variables with personally identifiable information [PII]) but, rather, will have access to aggregate deidentified data for reporting. CDC will have “read” access to the individualized survey data, including PII, provided by Oracle. On a continuous basis (either daily or weekly), these survey data will be accessible to CDC through downloads from the secure server.²²

The V-Safe Protocol further states, “No PII [personally identifiable information] will be included in any v-safe analyses, manuscripts, or data sets shared through external data requests.”²³

21. The CDC’s V-Safe Protocol stresses the importance of this data and that it “is anticipated that v-safe data will be shared with the scientific community and with the public through manuscripts and public reports.”²⁴ Despite these claims, v-safe data is not yet available to the public.

22. To ensure that the CDC acts in furtherance of its commitment to “openness and

¹⁹ <https://www.cdc.gov/vaccinesafety/pdf/V-safe-Protocol-508.pdf> (last visited May 11, 2022).

²⁰ *Id.* at 3.

²¹ *Id.* at 8.

²² *Id.* at 9 (emphasis added).

²³ *Id.* at 10.

²⁴ *Id.* at 12.

accountability” and to gain access to critical data regarding the safety of COVID-19 vaccines, Plaintiff made a FOIA request to the CDC for information regarding v-safe.

C. The FOIA Request (IR#0738)

23. On April 1, 2022, Plaintiff submitted the FOIA Request to the CDC seeking:

All data submitted to v-safe since January 1, 2020.

(Exhibit 2.)

24. On April 2, 2022, the CDC emailed Plaintiff and assigned its FOIA request Case Number 22-01281-FOIA. **(Exhibit 3.)**

25. On April 6, 2022, the CDC issued an acknowledgment letter to Plaintiff which stated in part:

The Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) received your Freedom of Information Act (FOIA) request dated April 1, 2022. Your request assigned number is #22-01281-FOIA, and it has been placed in our complex processing queue (copy enclosed).

(Exhibit 4.)

26. The acknowledgment letter also detailed that the agency “will require more than thirty working days to respond to [Plaintiff’s] request because: We reasonably expect to consult with two or more C/I/O/s, or another HHS operating division or another federal agency about your request.” *Id.*

27. Despite the passing of more than thirty days, Plaintiff has received no other communication from CDC regarding this FOIA request.

ARGUMENT

28. HHS and CDC failed to timely respond to Plaintiff’s FOIA request. 5 U.S.C. § 552(a)(6)(A)(i).

29. Despite the passing of more than thirty days, to date, CDC has not provided ICAN with a determination of whether it intends to comply with the FOIA Request as required by 5 U.S.C. § 552(a)(6)(A)(i). *Citizens for Responsibility & Ethics in Wash. v. FEC*, 711 F.3d 180, 188-89 (D.C. Cir. 2013) (“[I]n order to make a ‘determination’ and thereby trigger the administrative exhaustion requirement, the agency must at least: (i) gather and review the documents; (ii) determine and communicate the scope of the documents it intends to produce and withhold, and the reasons for withholding any documents; and (iii) inform the requester that it can appeal whatever portion of the ‘determination’ is adverse.”) When an agency takes more than thirty days to provide a ‘determination’ an “agency cannot rely on the administrative exhaustion requirement to keep cases from getting into court.” *Id.* at 189.

30. For these reasons, CDC has failed to abide by the requirements of FOIA and has forced ICAN to come before this Court to seek an order directing CDC to expeditiously produce all documents responsive to its FOIA request. The information ICAN seeks is simply too important to the current public discourse and safety monitoring regarding the COVID-19 vaccines to allow CDC to withhold such information from the public.

31. It is public knowledge that the data submitted to v-safe exists, therefore, that data should be produced to Plaintiff and the public forthwith.

REQUESTS RELIEF

WHEREFORE, Plaintiff prays that this Court:

- a. Provide for expeditious proceedings in this action;
- b. Enter an order directing the CDC to produce all v-safe data within one day from the date of any such order;
- c. Enter an order directing the CDC to produce all other documents responsive to

- each of the FOIA Requests within 10 days from the date of any such order;
- d. Award Plaintiff its costs and reasonable attorneys' fees incurred in this action as provided by 5 U.S.C. § 552(a)(4)(E); and
- e. Grant such other and further relief as the Court may deem just and proper.

Dated: May 17, 2022

SIRI & GLIMSTAD LLP



Aaron Siri, Bar No. 4321790
Elizabeth A. Brehm, NY Bar No. 4660353
(*pro hac vice* to be filed)
Colin M. Farnsworth, OR Bar No. 213351
(*pro hac vice* to be filed)
200 Park Avenue
17th Floor
New York, New York 10166
Tel: (212) 532-1091
aaron@sirillp.com
ebrehm@sirillp.com
cfarnsworth@sirillp.com

Attorneys for Plaintiff

Exhibit 1

DECLARATION OF CATHARINE LAYTON

STATE OF TEXAS

COUNTY OF HAYS

I, Catharine Layton, being duly sworn on oath do say:

1. I am the Chief Operating Officer of the Informed Consent Action Network (ICAN), a not-for-profit 501(c)(3) organization whose mission is to disseminate scientific health information to the public.

2. I have been an officer of ICAN since its founding in 2016. I oversee all day-to-day operations of the organization and all ICAN's programs. Together with our CEO and Board, I ensure that all efforts are focused on our mission statement and ensure that ICAN stays in compliance with all required rules and regulations.

3. In pursuit of its mission, ICAN relies primarily on its own investigative reporting. ICAN is both instrumental in orchestrating cutting edge investigations into the safety of various medical products, as well as widely disseminating its findings through various media channels. Most notably, ICAN's popular website hosts the organization's largest education program, The HighWire with Del Bigtree. Utilizing its media teams' 40+ years of experience in TV production and investigative journalism, The HighWire provides hours of new video content to the public each week for free.

4. The HighWire website has approximately 3.4 million weekly visitors. On Twitter, The HighWire has approximately 140,000 followers and 1 to 2.5 million impressions in a 28-day period. Between Rumble and Bitchute, The HighWire has approximately 60,000 followers and growing. Additionally, ICAN has 29,000 text subscribers and 194,245 email subscribers.


5. The size of ICAN's audience and subscribers continues to grow and is illustrative of the wide public interest in the subject of health and medical safety. Moreover, critical to ICAN's mission is its proven ability to find and review critical scientific and governmental records and meaningfully report about their social impacts.

6. One of the tools ICAN uses to gather the raw material it uses in its popular investigative reporting is the Freedom of Information Act (FOIA).


7. ICAN uses records it obtains from its FOIA requests to carry out its public mission and support its role as a non-profit news-media organization in the field of health and medical safety, but as a non-profit, ICAN does not have a commercial interest in the records it seeks through FOIA.

8. Based on what I know as the Chief Operating Officer, as well what has been demonstrated by ICAN's past and current investigative reporting, for purposes of FOIA's Fee Waiver provisions, ICAN certainly qualifies as a "representative of the news media."

Signed 3 day of May 2022


Signature of Catharine Layton

I, Amy Blackwell Notary public for the state of Texas witnessed
said Catharine Layton sign the above statement this 3 day of May, 2022
(month)

Notary Public for 




Exhibit 2



NEW YORK | LOS ANGELES | MIAMI
PHOENIX | DETROIT | DENVER | AUSTIN

200 Park Avenue, 17th Floor, New York, NY 10166
sirillp.com | P: (212) 532-1091 | F: (646) 417-5967

CDC FREEDOM OF INFORMATION ACT REQUEST

VIA ONLINE PORTAL

April 1, 2022

Roger Andoh
Freedom of Information Officer
Centers for Disease Control and Prevention
1600 Clifton Road, N.E., Building 57, Room MS D-54
Atlanta, Georgia 30333

Re: All Data Submitted to v-safe (IR#0738)

Dear Sir or Madam:

This firm represents the Informed Consent Action Network (“ICAN”). On behalf of ICAN, please provide the following records to foia@sirillp.com in electronic form:

All data submitted to v-safe since January 1, 2020.

We ask that you waive any and all fees or charges pursuant to 5 U.S.C. § 552(a)(4)(A)(iii). ICAN is a not-for-profit news media organization whose mission is to raise public awareness about vaccine safety and to provide the public with information to give informed consent. As part of its mission, ICAN actively investigates and disseminates information regarding vaccine safety issues for free, including through its website,¹ a weekly health news and talk show,² and through press events and releases. ICAN is seeking the information in this FOIA request to allow it to contribute to the public understanding of the government’s vaccine safety programs, including the government’s efforts to promote vaccine safety. The information ICAN is requesting will not contribute to any commercial activities.

Please note that the FOIA provides that if only portions of a requested file are exempted from release, the remainder must still be released. We therefore request that we be provided with all non-exempt portions which are reasonably segregable. We further request that you describe any deleted or withheld material in detail and specify the statutory basis for the denial as well as your reasons for believing that the alleged statutory justification applies. Please also separately state your reasons for not invoking your discretionary powers to release the requested documents

¹ <https://www.icandecide.org/>.

² <https://thehighwire.com/>.

in the public interest. Such statements may help to avoid unnecessary appeal and litigation. ICAN of course reserves all rights to appeal the withholding or deletion of any information.

Access to the requested records should be granted within twenty (20) business days from the date of your receipt of this letter. Failure to respond in a timely manner shall be viewed as a denial of this request and ICAN may immediately take further action.

Furthermore, we specifically request that the agency provide us with an estimated date of completion for this request.

If you would like to discuss our request or any issues raised in this letter, please feel free to contact us at (212) 532-1091 or foia@sirillp.com during normal business hours. Thank you for your time and attention to this matter.

Very truly yours,

/s/ Aaron Siri

Aaron Siri, Esq.

Elizabeth A. Brehm, Esq.

Colin M. Farnsworth Esq.

Exhibit 3

Annalise Beube

From: Centers for Disease Control and Prevention / Agency for Toxic Substances and Disease Registry
<foiarequests@cdc.gov>
Sent: Saturday, April 2, 2022 1:01 AM
To: S&G Information Request Staff
Subject: Status Update for Request #22-01281-FOIA

Follow Up Flag: Follow up
Flag Status: Flagged

Dear Aaron Siri,

The status of your FOIA request #22-01281-FOIA has been updated to the following status 'Received'. To log into the CDC FOIA Public Access Link click on the Application URL below.

<https://foia.cdc.gov/>

Sincerely,
FOIA

Exhibit 4



Centers for Disease Control
and Prevention (CDC)
Atlanta GA 30333

April 6, 2022

SENT VIA EMAIL

Aaron Siri
Siri & Glimstad LLP
200 Park Avenue
17th Floor
New York, NY 10166
Via email: foia@sirillp.com

Dear Mr. Siri:

The Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) received your Freedom of Information Act (FOIA) request dated April 1, 2022. Your request assigned number is #22-01281-FOIA, and it has been placed in our complex processing queue (copy enclosed).

Extension of Time

In unusual circumstances, an agency can extend the twenty-working-day limit to respond to a FOIA request.

We will require more than thirty working days to respond to your request because:

We reasonably expect to consult with two or more C/I/O/s, or another HHS operating division or another federal agency about your request.

To process your request promptly, please consider narrowing the scope of your request to limit the number of responsive records. If you have any questions or wish to discuss reformulation or an alternative time frame for the processing of your request, you may contact the analyst handling your request Irma Diaz at 770-488-6310 or our FOIA Public Liaison, Roger Andoh at 770-488-6277. Additionally, you may contact the Office of Government Services (OGIS) to inquire about the FOIA mediation services they offer. The contact information for OGIS is as follows: Office of Government Information Services; National Archives and Records Administration; 8601 Adelphi Road-OGIS; College Park, Maryland 20740-6001; e-mail at ogis@nara.gov; telephone at 202-741-5770; toll free at 1-877-684-6448; or facsimile at 202-741-5769.

Fees and Fee Waivers

You requested that we waive fees associated with processing your request, your request is granted, however we may charge reduced fees instead of waiving all fees. If we decide to charge reduced fees you will be notified.

Fee Category


Because you are considered an "Other requester" you are entitled to two hours of free search time, and up to 100 pages of duplication (or the cost equivalent of other media) without charge, and you will not be charged for review time. We may charge for search time beyond the first two hours and for duplication beyond the first 100 pages. (10 cents/page).

Cut-off-date

If you don't provide us with a date range for your request, the cut-off date for your request will be the date the search for responsive records starts.

You may check on the status of your case on our FOIA webpage <https://foia.cdc.gov/app/Home.aspx> and entering your assigned request number. If you have any questions regarding your request, please contact me at 770-488-6310 or via email at jy09@cdc.gov.

Sincerely,

A handwritten signature in black ink, appearing to read 'R. Andoh', written in a cursive style.

Roger Andoh
CDC/ATSDR FOIA Officer
Office of the Chief Operating Officer
Phone: (770) 488-6399
Fax: (404) 235-1852

22-01281-FOIA